Post-Genomics Blog

Forging a connection between research and clinical applications.

Biomarkers Europe

Biomarkers Europe

10-11 November 2008
Vienna, Austria

  • Clinical Biomarkers
  • Pharmacogenomics
  • Biomarker Assay Development
  • Biomarkers in Clinical Pharmacology
  • Biomarkers for Patient Selection
  • Toxicity Biomarkers
  • ‘Omic’ Biomarkers
  • Regulatory Perspective
  • Revolutionary Genome Sequencing Technologies – The $1000 Genome (R01)

    Revolutionary Genome Sequencing Technologies – The $1000 Genome (R01)

    Purpose: The National Human Genome Research Institute (NHGRI) solicits R01 grant applications to develop novel technologies that will enable extremely low-cost, high quality DNA sequencing. The goal of this initiative is to reduce the cost of sequencing a mammalian-sized genome to approximately $1000. Applicants may propose to develop full-scale sequencing systems or to investigate challenges underlying key system components. Exploration of methods other than those currently being pursued as potential $1,000 genome technologies are particularly encouraged. High-risk/high-payoff proposals are appropriate to achieve the goals of this FOA by approximately 2014

    Also see the following related funding initiatives:

    Revolutionary Genome Sequencing Technologies – The $1000 Genome (R21)

    Revolutionary Genome Sequencing Technologies – The $1000 Genome (SBIR [R43/R44])

    Revolutionary Genome Sequencing Technologies – The $1000 Genome (STTR [R41/R42])

    Website by Visual Flavors
    Valid XHTML 1.0 Transitional
    Valid CSS!
    We subscribe to the HONcode principles of the HON Foundation. Click to verify.